

Topping-Off Ceremony for the New Cell Culture Technology Center at Sartorius Stedim Biotech

Ulm, Germany, October 12, 2018 – Sartorius Stedim Biotech held its topping-off ceremony for the new Cell Culture Technology Center at Science Park III located in the scientific hub of Ulm, Germany. This laboratory and office facility covering 6,000 square meters will approximately double the space available so far at Sartorius Stedim Biotech's current site in Laupheim. With the building shell now completed, this investment of around 30 million euros has been progressing on schedule. Relocation from the company's present site to Ulm is scheduled for the end of 2019.

"This facility will be giving us new possibilities to meet the requirements of our customers and to grow as a company in a promising market of the future," said Reinhard Vogt, Executive Board member at Sartorius AG.

As a partner of the biopharmaceutical industry, the company in Laupheim has been developing cell lines and protein production processes, licensing technologies for manufacturing proteins and offering cell culture media and will continue to do so in the future at its new Cell Culture Technology Center in Ulm. Proteins produced by living cells are used in the development and manufacture of medications. Sartorius Stedim Biotech acquired the Laupheim-based company Cellca in 2015, which had about 30 employees. Meanwhile, approximately 100 people work at this site. After its relocation, the company plans to increase its workforce in Ulm to more than 120.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2017, Sartorius Stedim Biotech employed approx. 5,100 people and earned sales revenue of €1,081.0 million.

Contact

Timo Lindemann | Corporate Communications

+49 (0)551.308.4724 | timo.lindemann@sartorius.com | www.sartorius.com